Molecular markers of pancreatic cancer:: development and clinical relevance

被引:46
作者
Fry, Lucia C. [1 ]
Moenkemueller, Klaus [1 ]
Malfertheiner, Peter [1 ]
机构
[1] Otto Von Guericke Univ, Div Gastroenterol Hepatol & Infect Dis, D-39120 Magdeburg, Germany
关键词
pancreatic cancer; molecular markers; CA; 19-9; K-ras; proteomics; DNA methylation; mitochondrial mutations;
D O I
10.1007/s00423-007-0276-0
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background The prognosis of pancreatic cancer remains poor, mainly because of its aggressive biological behaviour and late clinical diagnosis, which precludes the application of appropriate curative therapies. Therefore, one of the major goals in clinical pancreatology is to find molecular markers, specific and sensitive enough to make an early and correct diagnosis of pancreatic cancer, before it has disseminated and become untreatable. Objective This overview article explores the potential utility of current molecular markers for the diagnosis of pancreatic cancer. Results There is a wide array of serum-based and tissue-based markers for pancreatic cancer. Serum-based molecular markers include CA 19-9, CA 125, M2-PK and secreted proteins. A tissue can be used to test genetic mutations such as K-ras, inactivation of tumour suppressor genes (e.g. p16, p53), mucins, telomerase activity, growth factors, DNA methylation, and global gene expression of cDNA microarrays, mitochondrial mutations and proteomics. None of these markers is currently useful for the detection of early pancreatic cancer. In clinical practice, the most commonly accepted use of CA 19-9 is to assess the prognosis and monitor the response to therapy. Conclusions Many molecular markers have been proposed for the early diagnosis of PC, but most are not ready to be included as part of the routine diagnostic algorithm because they still lack sensitivity, specificity or reproducibility. CA 19-9 remains the most useful molecular marker for the diagnosis and follow-up of clinically and radiological evident pancreatic cancer.
引用
收藏
页码:883 / 890
页数:8
相关论文
共 88 条
[21]   Molecular markers of early pancreatic cancer [J].
Goggins, M .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (20) :4524-4531
[22]  
Han HY, 2002, CANCER RES, V62, P2890
[23]   Possible detection of pancreatic cancer by plasma protein profiling [J].
Honda, K ;
Hayashida, Y ;
Umaki, T ;
Okusaka, T ;
Kosuge, T ;
Kikuchi, S ;
Endo, M ;
Tsuchida, A ;
Aoki, T ;
Itoi, T ;
Moriyasu, F ;
Hirohashi, S ;
Yamada, T .
CANCER RESEARCH, 2005, 65 (22) :10613-10622
[24]  
Hruban RH, 2000, CLIN CANCER RES, V6, P2969
[25]   Concordant loss of MTAP and p16/CDKN2A expression in pancreatic intraepithelial neoplasia: evidence of homozygous deletion in a noninvasive precursor lesion [J].
Hustinx, SR ;
Leoni, LM ;
Yeo, CJ ;
Brown, PN ;
Goggins, M ;
Kern, SE ;
Hruban, RH ;
Maitra, A .
MODERN PATHOLOGY, 2005, 18 (07) :959-963
[26]   Differentially expressed genes in pancreatic ductal adenocarcinomas identified through serial analysis of gene expression [J].
Hustinx, SR ;
Cao, DF ;
Maitra, A ;
Sato, N ;
Martin, ST ;
Sudhir, D ;
Iacobuzio-Donahue, C ;
Cameron, JL ;
Yeo, CJ ;
Kern, SE ;
Goggins, M ;
Mollenhauer, J ;
Pandey, A ;
Hruban, RH .
CANCER BIOLOGY & THERAPY, 2004, 3 (12) :1254-1261
[27]  
Iacobuzio-Donahue CA, 2003, CANCER RES, V63, P8614
[28]   Discovery of novel tumor markers of pancreatic cancer using global gene expression technology [J].
Iacobuzio-Donahue, CA ;
Maitra, A ;
Shen-Ong, GL ;
van Heek, T ;
Ashfaq, R ;
Meyer, R ;
Walter, K ;
Berg, K ;
Hollingsworth, MA ;
Cameron, JL ;
Yeo, CJ ;
Kern, SE ;
Goggins, M ;
Hruban, RH .
AMERICAN JOURNAL OF PATHOLOGY, 2002, 160 (04) :1239-1249
[29]  
Jiang Xiao-Ting, 2004, Hepatobiliary Pancreat Dis Int, V3, P464
[30]   Implications of growth factor alterations in the treatment of pancreatic cancer [J].
Márk Juhász ;
Barbara Nitsche ;
Peter Malfertheiner ;
Matthias PA Ebert .
Molecular Cancer, 2 (1)